Over the last two years we have been conducting a double blind placebo controlled trial of Towne strain live cytomegalovirus vaccine in renal transplant candidates. The data accumulated thus far indicate that the vaccine prevents severe CMV disease, but not infection. This appears to be true despite the fact that the vaccinees are immunosuppressed. The current grant request is first for funds to allow the completion of the study: i.e., to enable the accumulation of sufficient numbers of patients to confirm statistical significance of protection, to allow for analysis of subgroups, and to allow for collection of data on long-term safety and persistence of immunity. In addition, booster effects in naturally immune subjects will also be studied. Up to this point, we have used lymphocyte proliferation as the assay of cellular immunity to CMV in the next period we will add newly developed assays of natural killer cell activity and of cytotoxic T cells. If we prove that artificially-induced immunity can be protective, and taking into account possible objections to live virus vaccine, we will extend our vaccine studies to glycoprotein preparations. With the aid of affinity chromatography using monoclonal antibodies to neutralizing glycoproteins we will purify antigens for use in immunization studies. The initial immunizations will be done in guinea pigs, to confirm our earlier work on subunit vaccine, followed by clinical trials in man. Since one of the long range objectives of this work is to develop a vaccine for immunization of normal women for the prevention of congenital disease, it is important to test the efficacy of Towne in immunologically normal individuals. In order to provide a uniform challenges, a pool of low-passage wild CMV has been prepared and safety-tested. A population of cloistered monks have volunteered to be immunized and then to be given the long passage virus as a test of the efficacy of vaccination in normal subjects. These efforts are all directed towards finding an effective immunologic strategy for the prevention of disease caused by CMV.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD018957-08
Application #
3316099
Study Section
Virology Study Section (VR)
Project Start
1978-05-01
Project End
1986-11-30
Budget Start
1985-05-01
Budget End
1986-11-30
Support Year
8
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Berencsi, K; Gonczol, E; Endresz, V et al. (1996) The N-terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 1 (UL123) induce a cytotoxic T-cell response. Vaccine 14:369-74
Berencsi, K; Uri, A; Valyi-Nagy, T et al. (1994) Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses. Lab Invest 71:350-8
Berencsi, K; Rando, R F; deTaisne, C et al. (1993) Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB. J Gen Virol 74 ( Pt 11):2507-12
Starr, S E (1992) Cytomegalovirus vaccines: current status. Infect Agents Dis 1:146-8
Gonczol, E; deTaisne, C; Hirka, G et al. (1991) High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 9:631-7
Plotkin, S A (1991) Cytomegalovirus vaccine development--past and present. Transplant Proc 23:85-9
Plotkin, S A; Starr, S E; Friedman, H M et al. (1990) Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis 12 Suppl 7:S827-38
Gonczol, E; Ianacone, J; Ho, W Z et al. (1990) Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8:130-6
Marshall, G S; Ricciardi, R P; Rando, R F et al. (1990) An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J Infect Dis 162:1177-81
Gonczol, E; Plotkin, S (1990) Progress in vaccine development for prevention of human cytomegalovirus infection. Curr Top Microbiol Immunol 154:255-74

Showing the most recent 10 out of 23 publications